Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print